Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Trial Details

NCT ID

NCT05766748

Phase

PHASE1 / PHASE2

Sponsor

Cantex Pharmaceuticals

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Azeliragon

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• Boca Raton, Florida, United States|26.35869,-80.0831
• Eugene, Oregon, United States|44.05207,-123.08675
• Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
• Greenville, South Carolina, United States|34.85262,-82.39401

Key Eligibility Criteria

• Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, suc…
• Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen.
• Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy).
• Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.